2025-11-05T18:08:17-06:00 2024-12-31 390859910 BAKER TILLY ADVISORY GROUP LP 4747 EXECUTIVE DR SUITE 1300 SAN DIEGO CA 92121 990 2024-01-01 521842938 J CRAIG VENTER INSTITUTE JCRA 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 JOHN CRAIG VENTER CHAIRMAN AND CEO 8582001800 2025-11-04 1 1 PATRICIA J MAYER P00188643 8586271400 2024 2025-03-06 01:10:19Z JOHN CRAIG VENTER 4120 CAPRICORN LANE LA JOLLA CA 92037 70623105 0 X WWW.JCVI.ORG X 1993 MD JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MORE ABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERS ABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL. 7 5 145 7 3172 0 15104824 12879736 0 0 18333 1524575 9582 3172 15132739 14407483 2483399 1536818 0 0 13562992 12647811 0 0 434753 5799283 5420240 21845674 19604869 -6712935 -5197386 48982028 39462295 10026647 8297989 38955381 31164306 X J. CRAIG VENTER INSTITUTE (JCVI) IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION ADVANCING THE SCIENCE OF GENOMICS COMMITTED TO ACCELERATING FOUNDATIONAL SCIENTIFIC RESEARCH TO DRIVE ADVANCES IN HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY. THIS PAST YEAR JCVI COMMITTED RESEARCH EFFORTS IN HUMAN HEALTH, ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, AND SOFTWARE TOOLS AND TECHNOLOGY. 0 0 5271780 770981 DEPARTMENT OF HEALTH AND HUMAN SERVICES: TWO MILLION PEOPLE IN THE U.S. ARE DIAGNOSED ANNUALLY WITH LIFE-THREATENING INFECTIONS CAUSED BY ANTIBIOTIC RESISTANT BACTERIA THAT ARE RESPONSIBLE FOR 35,000 DEATHS EACH YEAR WITH AN ECONOMIC IMPACT ESTIMATED TO BE AS MUCH AS $20 BILLION A YEAR IN DIRECT HEALTHCARE COSTS. DUE TO THE SPREAD OF ANTIBIOTIC RESISTANCE, VERY FEW DRUGS REMAIN THAT CAN TREAT THESE INFECTIONS. LED BY DERRICK FOUTS, PHD, (JCVI) AND FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE J. CRAIG VENTER INSTITUTE AND CLEVELAND VA PREVENTION AND INTERVENTION EPICENTER ARE DEVELOPING NOVEL INTERVENTIONS THAT WILL PREVENT THE COLONIZATION AND SPREAD OF ANTIBIOTIC RESISTANT (AR) BACTERIA THAT CAUSE HOSPITAL ACQUIRED INFECTIONS (HAI), AND TO DEVELOP DIAGNOSTICS AND INTERVENTIONS TO COMBAT THE COLONIZATION BY THE RAPIDLY EMERGING FUNGAL PATHOGEN CANDIDA AURIS. COLLABORATORS ON THIS MULTI YEAR FUNDED CENTER INCLUDE RESEARCH LABS AT DUKE UNIVERSITY, CASE WESTERN UNIVERSITY AND NORTHWESTERN UNIVERSITY. LED BY INDRESH SINGH, DIRECTOR OF INFORMATICS, THE JCVI IS A KEY COLLOBORATOR FOR THE BACTERIAL AND VIRAL BIOINFORMATICS RESOURCE CENTER (BV-BRC). USING THE ADVANCED SYSTEM ARCHITECTURE BASED ON HIGH-PERFORMANCE COMPUTING, EXTENSIBLE DATABASE MANAGEMENT APPROACH STRUCTURED ON EMERGING METADATA STANDARDS, AND SUITE OF ANALYSIS AND VISUALIZATION TOOLS AND SERVICES AVAILABLE FOR CUSTOMIZED WORKFLOW ASSEMBLY JCVI SUPPORTS ONGOING DEVELOPMENT OF THE COMPREHENSIVE INTEGRATED BV-BRC THROUGH A TEAM OF VIROLOGY, IMMUNOLOGY, BIOINFORMATICS, AND INFORMATION TECHNOLOGY PROFESSIONALS WHO FOCUS ON THE DEVELOPMENT, ENHANCEMENT, AND TRAINING OF THE BV-BRC RESOURCE FOR THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, THEIR SUPPORTED RESEARCHERS, AND THE BROADER INFECTIOUS DISEASE RESEARCH COMMUNITY. INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE ARE INCREASINGLY PREVALENT AND DIFFICULT TO TREAT DUE TO INEFFECTIVE TREATMENT OPTIONS DUE TO INCREASED ANTIBIOTIC RESISTANCE. BACTERIOPHAGES, VIRUSES THAT INFECT AND KILL BACTERIA, ARE BEING USED TO EFFECTIVELY TREAT AND CURE INFECTIONS CAUSED BY A NUMBER OF BACTERIAL PATHOGENS. TO ADDRESS THE NEED FOR NEW TREATMENTS FOR WOUND AND PULMONARY INFECTIONS CAUSED BY K. PNEUMONIAE, DR. DERRICK FOUTS TEAM HAS DEVELOPED A 5-PHAGE LEAD CANDIDATE THERAPEUTIC COCKTAIL THAT IS CAPABLE OF INFECTING 53 OF OUR 100-STRAIN TEST PANEL. FUNDED BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, THE JCVI, THE WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) AND ADAPTIVE PHAGE THERAPEUTICS (APT) WILL OPTIMIZE THE LEAD THERAPEUTIC AND ITS PRODUCTION AS WELL AS CONDUCT THE REQUIRED PREINVESTIGATIONAL NEW DRUG (IND) TESTING AND BENCHMARKING NECESSARY FOR THE SUCCESSFUL SUBMISSION AND REVIEW OF AN IND APPLICATION FOR A PHASE 1 CLINICAL TRIAL. RESEARCH WILL LEVERAGE JCVI'S HISTORY OF SYNTHETIC AND PHAGE GENOMICS, WRAIR'S EXPERIENCE DEVELOPING PHAGE THERAPEUTICS, DEVELOPMENT OF MOUSE MODELS, AND APTS CGMP PRODUCTION CAPABILITIES AND EXPERIENCE WITH PHAGE CLINICAL TRIALS. 1128103 200684 NATIONAL SCIENCE FOUNDATION CONTINUES TO FUND THE J. CRAIG VENTER INSTITUTE (JCVI) IN THE AREAS OF SYNTHETIC BIOLOGY, INTEGRATIVE ORGANISMAL SYSTEMS CORE PROGRAMS. FUNDED BY THE OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING, DR. TAE SEOK MOON, JCVI PROFESSOR LEADS AN INTERNATIONAL CONSORTIUM THROUGH A GLOBAL CENTER TO ADDRESS THE CHALLENGES OF RECALCITRANT WASTE STREAMS BY DEVELOPING INTEGRATED, NOVEL, AND SCALABLE PROCESSES FOR THEIR VALORIZATION, INTEGRATING RESEARCHERS ALL OVER THE WORLD AND FROM ACADEMIA AND INDUSTRY, AND PROVIDING GLOBAL EDUCATION, OUTREACH ACTIVITIES, AND WORKFORCE. GLOBAL CENTERS: CIRCLE: CENTER FOR INNOVATIVE RECYCLING AND CIRCULAR ECONOMY IS SUPORTED BY RESEARCH TEAMS IN THE UNITED STATES, CANADA, UNITED KINGDOM, KOREA, JAPAN, SINGAPORE & AUSTRALIA. THIS CENTER WILL DEVELOP THREE CORE TECHNOLOGIES, INCLUDING (1) MULTI-OMICS-BASED BIOPROSPECTING TO DISCOVER NEW ENZYMES, GENE REGULATORS, AND ORGANISMS FOR WASTE VALORIZATION, (2) PREDICTIVE COMPUTATIONAL APPROACHES TO ENABLE FORWARD ENGINEERING OF PROTEINS AND STRAINS FOR BIOMANUFACTURING, AND (3) TEA, LCA, AND RISK ASSESSMENT TO DEVELOP COMMERCIALLY VIABLE BIOPROCESSES FOR WASTE VALORIZATION. TO DEMONSTRATE THE UTILITY AND GENERALIZABILITY OF THE DEVELOPED CORE TECHNOLOGIES, WE WILL DEVELOP COMMERCIALLY VIABLE VALORIZATION PROCESSES FOR THREE WASTE STREAMS, INCLUDING MIXED PLASTICS, C1 GASES, AND BIOGENIC WASTES (E.G., FOOD, AGRICULTURAL, AND PAPER/CARDBOARD WASTES). IF SUCCESSFUL, THESE HIGH-RISK, HIGH-RETURN CENTER PROJECTS WILL PROVIDE NOVEL WASTE CONVERSION PROCESSES THAT CAN BE CONSIDERED FOR COMMERCIAL-SCALE, SUSTAINABLE BIOPRODUCTION. THIS IS MULTI-YEAR INTERNATIONAL STUDY. THE US CONSORTIUM HAS BEEN FUNDED UPTO $4.9M. NON-US COLLABORATORS HAVE BEEN FUNDED THROUGH RESEARCH AGENCIES WITHIN THEIR OWN COUNTRIES. UNDER THE DIVISION OF MOLECULAR AND CELLULAR BIOSCIENCE AND IN COLLABORATION WITH THE UNIVERSITY OF ILLINOIS MINIMAL BACTERIAL CELL COMPUTATIONAL MODELEING TEAM LED BY ZAIDA LUTHEY-SCHULTEN, JCVI RESEARCHERS LED BY DR. JOHN GLASS, ARE CARRYING OUT TRANSCRIPTOME AND METABLOMIC ANALYSES, BIOCHEMICAL AND GENETIC EXPERIEMENTS TO DISCOVER UNKNOWN GENE FUNCTIONS, OPTIMIZATION OF A MINIMAL CELL DEFINED GROWTH MEDIUM, AND CONSTRCUTION OF MINIMAL CELL MUTATNS TO FACILITATE THE WORK OF JCVI AND OTHER GROUP[S INVESTIGATING MINIMAL CELL BIOLOGY. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $2.0M (~$0.7M JCVI).LED BY DR. JOHN GLASS, THE JCVI IS INVESTIGATING THE MECHANISM OF GENOME TRANSPLANTATION, DEVELOP GENOME TRANSPLANTATION FOR AT LEAST TWO SPECIES OF NON-MYCOPLASMA BACTERIA, AND USE MICROFLUIDICS TECHNOLOGY TO AUTOMATE AND IMPROVE THE EFFICIENCY OF GENOME TRANSPLANTATION. GENOME TRANSPLANTATION, THE INSERTION OF A COMPLETE BACTERIAL GENOME INTO A SUITABLE RECIPIENT CELL SO THAT THE DONATED GENOME COMMANDEERS THE RECIPIENT CELL TO PRODUCE A NEW CELL WITH THE GENOTYPE AND PHENOTYPE OF THE DONATED GENOME, WAS THE FUNDAMENTAL TECHNICAL DEVELOPMENT THAT ENABLED THE CONSTRUCTION OF THE FIRST BACTERIUM WITH A SYNTHETIC GENOME. AT THE ANNOUNCEMENT OF THE CREATION OF THE WORLD'S FIRST SYNTHETIC CELL, JCVI-SYN1.0, THE WORK WAS HERALDED AS A MAJOR ACCOMPLISHMENT FOR HUMANKIND. TO DATE, GENOME TRANSPLANTATION HAS ONLY BEEN ACHIEVED USING A SMALL SUBSET IF THE ATYPICAL BACTERIA CALLED MYCOPLASMAS. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $1.0M. 2066947 565153 JCVI SCIENTISTS HAVE PARTNERED WITH OTHER SCIENTISTS FROM LEADING ACADEMIC CENTERS TO COME TOGETHER TO ANSWER KEY QUESTIONS ABOUT THE ROOT CAUSE OF LONG COVID WHETHER FRAGMENTS OF THE CORONAVIRUS PERSIST IN THE TISSUES OF PATIENTS. THE LONG COVID RESEARCH INITITATIVE BANDS TOGETHER SCIENTSITS FROM HARVARD UNIBVERSITY, STANFORD UNIVERSITY, THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, YALE UNIVERSITY AND THE J. CRAIG VENTER INSTITUTE. THE INITITATIVE IS BACKED BY AN INITITIAL INVESTMENT FROM THE BALVI, A SCIENTIFC INVESTMENT FUND. JCVI FUNDING IS AWARDED THROUGH THE POLYBIO RESEARCH FOUNDATION. RESEARCHERS ARE USING ADVANCED IMAGING AND GENE-SEQUENCING TECHNIQUES LOOKING FOR EVIDENCE OF THE VIRUS IN TISSUES AND ANALYZING ITS AFFECT ON THE IMMUNE SYSTEM. OVER THE LAST FEW YEARS, ADVANCES IN STEM CELL RESEARCH AND SYNTHETIC BIOLOGY HAVE CATALYZED AN EXTRAORDINARY EXPANSION OF ORGANOID TECHNOLOGY THAT IS BRINGING CHANGES TO TRANSLATIONAL MEDICINE, PHARMACEUTICAL RESEARCH, AND STRATEGIES FOR TREATING VARIOUS HUMAN PATHOLOGIES. USING STEM CELLS, ORGANOIDS HAVE BEEN DEVELOPED FOR MULTIPLE ORGANS INCLUDING LIVER, INTESTINE, KIDNEY, BRAIN, STOMACH, SKIN, OVARY, AND LUNG. FUNDED BY THE LARRY L HILLBLOM FOUNDATION, DR. JOHN GLASS IS LEADING A CONSORTIUM OF RESEARCHERS THAT PROPOSE TO DEVELOP ORGANOIDS THAT CAN SERVE AS SURROGATES FOR BETA CELLS, WHICH ARE THE CELLS IN THE HUMAN PANCREAS THAT CONTROL BLOOD GLUCOSE LEVELS BY SYNTHESIZING INSULIN. OUR GOAL IS THAT THESE ORGANOIDS, WHEN IMPLANTED IN TYPE 1 DIABETICS, WILL RESULT IN A BETTER TREATMENT AND BETTER LIVES FOR THOSE PATIENTS. 451688 OTHER RELATED PROGRAMS FOR SUPPORT OF DEVELOPMENT OF KEY STAFF & INTERNSHIPS. 451688 8918518 1 1 0 0 0 0 0 1 0 0 1 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 14 0 1 145 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 7 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC ND NH NJ VA X KATHARINE WARDLE 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 VENTER JOHN CRAIG CHAIRMAN & CHIEF EXECUTIVE OFFICER 40.00 X X 1190475 0 23056 KOWALSKI HEATHER CHIEF OPERATING OFFICER 40.00 X X 359212 0 23056 WOLF RICHMOND TRUSTEE 1.00 X 0 0 0 RUGGLES RUDY VICE CHAIRMAN, TRUSTEE 1.00 X 0 0 0 PERRY MEREDITH TRUSTEE 1.00 X 0 0 0 BRENNER DAVID TRUSTEE 1.00 X 0 0 0 BADR-EL-DIN AMIN PHD TRUSTEE 1.00 X 0 0 0 WARDLE KATHARINE TREASURER,VP OF FINANCE 40.00 X 260155 0 46857 ADELSON JULIE G SECRETARY, VP LEG AFFAIRS 20.00 X 196807 0 7224 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 40.00 X 302196 0 13693 VASHEE SANJAY PROFESSOR 40.00 X 207306 0 8501 MULLEN JILL SR. VP OF PHILANTHROPY 32.00 X 281793 0 36768 YUMUL MARY C VP OF HUMAN RESOURCES 40.00 X 252063 0 42075 STAYEAS TIMOTHY V NETWORK TEAM LEAD 40.00 X 212799 0 37870 FOUTS DERRICK PROFESSOR 40.00 X 214560 0 8512 SINGH INDRESH DIRECTOR, INFORMATICS 40.00 X 206595 0 37301 3683961 0 284913 30 0 1 0 MOSS ADAMS LLP 4747 EXECUTIVE DRIVE SUITE 1300 SAN DIEGO CA 92121 ACCOUNTING AND AUDIT SERVICES 154010 1 10249834 2629902 12879736 96101 96101 57644096 56215274 348 1428822 -348 1428474 1428474 K-1 PASSTHROUGH 900001 3172 3172 3172 14407483 0 3172 1524575 1536818 1536818 2638537 215807 2422730 6793385 4145921 2386655 260809 274371 138818 125949 9604 2219275 1036573 1115734 66968 722243 312323 389560 20360 94545 94545 155770 155770 89353 89353 135480 48318 86687 475 872349 196719 672007 3623 1441888 1393958 47930 300462 206645 78252 15565 383399 146222 237177 405624 405624 1541370 934354 597597 9419 19604869 8918518 10251598 434753 2971911 2845665 1274704 122986 13669583 7959702 11598 3433 576720 394598 12491463 11237051 1606408 1254412 23360705 21846951 553787 409403 0 10000 4956612 4615145 48982028 39462295 2674079 2433509 4052856 3025407 3299712 2839073 10026647 8297989 X 29780872 24994329 9174509 6169977 38955381 31164306 48982028 39462295 X -5197386 379483 -2973172 X 0 1 X 1 1 1 X 18613419 24288254 16500408 15104824 12879736 87386641 14850000 14850000 18613419 24288254 31350408 15104824 12879736 102236641 102236641 905885 855862 726080 627098 96101 3211026 15119 5836 20955 105468622 249402 0.96940 0.96270 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2545000 X X X 0 1395244 780809 614435 10777454 10137477 639977 318765 318765 0 1254412 OTHER ASSETS 2715329 RIGHT OF USE ASSETS 1899816 4615145 LEASE LIABILITY 2839073 2839073 X 14694441 379483 379483 14314958 89353 3172 92525 14407483 22485516 2970000 2970000 19515516 89353 89353 19604869 PART III, LINE 4: COLLECTION OF SCIENTIFIC WRITINGS RELEVANT TO GENOMIC RESEARCH. PART X, LINE 2: THE INSTITUTE IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE INSTITUTE DOES NOT BELIEVE THERE ARE ANY MATERIAL UNCERTAIN TAX POSITIONS AND ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE INSTITUTE IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIOD IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: K-1 PASSTHROUGH 3,172. 1 CAYMAN ISLANDS 0 0 INVESTMENTS 145119 0 0 0 0 0 0 145119 0 145119 0 0 0 0 1 0 PART I, LINE 3: ACCRUAL BASIS PART II, LINE 1: ACCRUAL BASIS 1 EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLR ATLANTA GA 303224250 580566256 501(C)(3) 354924 0 RESEARCH SUBGRANT CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE NORD HALL CLEVELAND OH 441067037 341018992 501(C)(3) 350485 0 RESEARCH SUBGRANT THE GENEVA FOUNDATION PO BOX 84212 SEATTLE WA 981245512 911593913 501(C)(3) 264577 0 RESEARCH SUBGRANT REGENTS U OF CA SAN DIEGO 9500 GILMAN DR LA JOLLA CA 92037 566001393 GOVT 197818 0 RESEARCH SUBGRANT DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 98012 0 RESEARCH SUBGRANT RHODE ISLAND HOSPITAL 1 HOPPIN STREET BOX 42 SUITE 1300 PROVIDENCE RI 029034923 050258954 501(C)(3) 78596 0 RESEARCH SUBGRANT NORTHWESTERN UNIVERSITY 633 CLARK ST G547 EVANSTON IL 60208 362167817 501(C)(3) 75371 0 RESEARCH SUBGRANT UNIVERSITY OF MARYLAND 4300 TERRAPIN TRAIL COLLEGE PARK MD 20742 526002033 GOVT 70249 0 RESEARCH SUBGRANT LAWRENCE LIVERMORE NATIONAL SECURITY LLC PO BOX 5516 LIVERMORE CA 94550 205624386 32770 0 RESEARCH SUBGRANT CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION 10701 EAST BLVD 151C W CLEVELAND OH 441061702 341710663 501(C)(3) 10089 0 RESEARCH SUBGRANT 9 1 PART I, LINE 2: EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. X 1 1 X X X X 0 0 0 0 0 0 0 0 0 VENTER JOHN CRAIG CHAIRMAN & CHIEF EXECUTIVE OFFICER 1159975 0 0 0 30500 0 13800 0 9256 0 1213531 0 0 0 KOWALSKI HEATHER CHIEF OPERATING OFFICER 341212 0 0 0 18000 0 13800 0 9256 0 382268 0 0 0 MULLEN JILL SR. VP OF PHILANTHROPY 256710 0 0 0 25083 0 11236 0 25532 0 318561 0 0 0 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 278965 0 0 0 23231 0 12145 0 1548 0 315889 0 0 0 WARDLE KATHARINE TREASURER,VP OF FINANCE 229655 0 0 0 30500 0 10835 0 36022 0 307012 0 0 0 YUMUL MARY C VP OF HUMAN RESOURCES 230830 0 0 0 21233 0 10434 0 31641 0 294138 0 0 0 STAYEAS TIMOTHY V NETWORK TEAM LEAD 189799 0 0 0 23000 0 9026 0 28844 0 250669 0 0 0 SINGH INDRESH DIRECTOR, INFORMATICS 181284 0 0 0 25311 0 8457 0 28844 0 243896 0 0 0 FOUTS DERRICK PROFESSOR 184060 0 0 0 30500 0 8512 0 0 0 223072 0 0 0 VASHEE SANJAY PROFESSOR 189326 0 0 0 17980 0 8501 0 0 0 215807 0 0 0 ADELSON JULIE G SECRETARY, VP LEG AFFAIRS 168007 0 0 0 28800 0 7224 0 0 0 204031 0 0 0 PART I, LINE 1A TAX INDEMIFICATION AND GROSS-UP PAYMENTS - CERTAIN AWARDS ARE GROSSED UP FOR INCOME TAX AND INCLUDED AS TAXABLE COMPENSATION. FORM 990, PART VI, SECTION A, LINE 2 BOARD MEMBERS HEATHER KOWALSKI AND J. CRAIG VENTER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY MANAGEMENT AND THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C JCVI MONITORS COMPLIANCE TO ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL SOLICITATION OF CONFLICT OF INTEREST STATEMENTS FROM TRUSTEES, OFFICERS, AND EMPLOYEES. IF A PERSON HAS A CONFLICT WITH RESPECT TO A TRANSACTION, SUCH PERSON IS NOT ALLOWED TO VOTE ON THAT TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 JCVI USES AN OUTSIDE COMPENSATION CONSULTANT TO PROVIDE A LIST OF COMPARABLE SALARIES FOR THE CEO AND OFFICERS. THESE ARE REVIEWED BY THE JCVI COMPENSATION COMMITTEE AND CEO BEFORE A FINAL DETERMINATION IS MADE. THIS PROCESS WAS DOCUMENTED AND LAST DONE IN OCTOBER 2018. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: K-1 PASSTHROUGH -3,172. DONATED RENT -2,970,000.